Real-world insulin stability and global access
- PMID: 37003281
- DOI: 10.1016/S2213-8587(23)00066-9
Real-world insulin stability and global access
Conflict of interest statement
MAW is co-founder of and holds equity in Thermalin, focused on ultra-fast, ultra-concentrated insulin analogues.
Comment on
-
Insulin thermostability in a real-world setting.Lancet Diabetes Endocrinol. 2023 May;11(5):310-312. doi: 10.1016/S2213-8587(23)00028-1. Epub 2023 Mar 29. Lancet Diabetes Endocrinol. 2023. PMID: 37003280 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical